Kisunla (donanemab-azbt) Patient Assistance Program
Don’t let the high cost of brand anti-amyloid antibody disrupt your early Alzheimer’s disease treatment. We help eligible patients access Kisunla (donanemab-azbt IV infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Kisunla (donanemab-azbt) is FDA-approved (2024) for treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of Alzheimer's disease (early symptomatic AD) with confirmed amyloid pathology. Anti-amyloid beta monoclonal antibody — targets aggregated amyloid plaques for clearance. Second anti-amyloid antibody approved (after Leqembi). May allow treatment cessation once amyloid clearance is achieved.
- Without assistance, Kisunla costs commonly run approximately $32,000+ per year (~$2,700/month).
- Through AffordMyPrescriptions, qualifying patients can access Kisunla for a flat $69.95 per month.
- Other anti-amyloid antibodies: Leqembi (lecanemab — brand; IV every 2 weeks, first FDA-approved amyloid antibody for AD after Aduhelm's withdrawal). Aduhelm (aducanumab) withdrawn from the US market in 2024. Symptomatic AD medications (generic): cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine (NMDA antagonist). Amyloid antibodies slow AD progression in select patients; symptomatic drugs improve cognitive symptoms. Comprehensive AD care: cognitive training, family support, driving safety, advance care planning. Alzheimer's Association resources.
What is Kisunla Prescription Assistance Program?
The Kisunla Patient Assistance Program helps eligible patients access this anti-amyloid antibody for early Alzheimer’s disease at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but involves detailed applications, neurology coordination, amyloid biomarker documentation, an MRI monitoring plan, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Kisunla PAP enrollment for a flat $69.95 per month — so you never face a gap in Kisunla Alzheimer’s therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Kisunla enrollment — so you never face a gap in your early Alzheimer’s disease treatment.
Pharmacy Price Comparison
- Without assistance, Kisunla costs thousands per month. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic donepezil (symptomatic) | ~$10/mo | Cheap symptomatic AD alt |
| Neurology infusion center | ~$2,800/mo | Save substantially |
| Community memory clinic | ~$2,700/mo | Save substantially |
| Hospital outpatient | ~$2,900/mo | Save substantially |
| 340B-eligible institution | ~$2,300/mo | Save substantially |
| Leqembi (alt anti-amyloid) | ~$2,300/mo | Alt anti-amyloid antibody |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Kisunla — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Kisunla Prescription Program?
The Kisunla Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Kisunla is disease-modifying — it slows AD progression in appropriately selected early-stage patients. It requires amyloid biomarker confirmation and MRI monitoring for ARIA. Alzheimer’s Association and dementia specialty care are essential.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Kisunla assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Kisunla is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Kisunla:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $2,700+ per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Kisunla assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Kisunla Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Kisunla:
Kisunla is an anti-amyloid beta monoclonal antibody — targeting aggregated amyloid plaques in Alzheimer’s disease for clearance. The second FDA-approved amyloid-targeting antibody. Unique among the class: it may allow treatment cessation once amyloid clearance is achieved (a potentially finite treatment course).
How It Works:
Alzheimer’s disease is the most common cause of dementia — characterized pathologically by amyloid beta plaques and tau tangles. Amyloid beta accumulation is thought to trigger downstream neurodegeneration. Historical AD medications (cholinesterase inhibitors, memantine) provide symptomatic benefit without slowing disease progression. Amyloid-targeting antibodies represent the first disease-modifying AD therapies. Donanemab is a monoclonal antibody targeting a specific form of aggregated amyloid beta (N-terminally truncated pyroglutamate amyloid — enriched in plaques). It binds and promotes microglial clearance of amyloid plaques, slowing cognitive and functional decline in early symptomatic AD (TRAILBLAZER-ALZ2 trial). Unique feature: it may allow treatment cessation once amyloid clearance is achieved by follow-up PET imaging. Related agent Leqembi (lecanemab) is the same mechanism class, different antibody, continuous treatment. Aduhelm (aducanumab) was withdrawn from the US market in 2024.
Form and Use:
Kisunla IV infusion every 4 weeks. Weight-based dosing. Given at a neurology infusion center or memory clinic. Requires baseline amyloid PET or CSF confirmation. MRI monitoring for amyloid-related imaging abnormalities (ARIA) — baseline and periodic during therapy. Treatment cessation may be considered upon achieving amyloid clearance on follow-up imaging.
Generic Availability:
No generic Kisunla. Other anti-amyloid antibodies for AD: Leqembi (lecanemab — brand; IV every 2 weeks; first FDA-approved amyloid antibody after Aduhelm; requires ongoing treatment). Aduhelm (aducanumab) withdrawn from the US market in 2024. Symptomatic AD medications (all generic): cholinesterase inhibitors (donepezil, rivastigmine, galantamine — for mild-moderate AD), memantine (NMDA antagonist — for moderate-severe AD). Comprehensive AD care includes geriatric assessment, cognitive training, family caregiver support, driving safety evaluation, advance care planning, and treatment of comorbid conditions. Alzheimer’s Association (alz.org) resources.
Warnings:
Amyloid-related imaging abnormalities (ARIA — including edema/effusion [ARIA-E] and hemorrhage/hemosiderin [ARIA-H] — frequently asymptomatic but can be serious; require MRI monitoring; higher risk in APOE ε4 homozygotes — genotype testing recommended before treatment; hold or discontinue for severe or symptomatic ARIA), infusion-related reactions, hypersensitivity reactions, embryo-fetal considerations. Other: headache, fall risk. APOE ε4 genotype testing and an MRI monitoring plan are essential before treatment. Neurology or memory specialty care is required.
FAQ (Frequently Asked Questions)
How much does Kisunla cost without insurance?
$32,000+ per year at neurology infusion centers (~$2,700/month). Leqembi (alternative anti-amyloid) is similarly priced. Symptomatic AD medications (donepezil, memantine — generic) are $10–$30/month with no disease-modifying effect but cheaper.
How is Kisunla different from Leqembi?
Both are anti-amyloid monoclonal antibodies for early symptomatic Alzheimer’s disease. Kisunla is IV every 4 weeks; Leqembi is IV every 2 weeks. Kisunla uniquely may allow treatment cessation once amyloid clearance is achieved on follow-up PET (a potentially finite course). Leqembi is continuous treatment. Different antibodies targeting different amyloid forms — clinical efficacy comparable overall.
Who is Kisunla for?
Adults with early symptomatic Alzheimer’s disease — mild cognitive impairment or mild dementia stage — with confirmed amyloid pathology (PET or CSF biomarkers). Not for moderate-severe AD. Neurology or memory specialty assessment. APOE ε4 genotype testing (higher ARIA risk in ε4 homozygotes).
What is ARIA?
Amyloid-Related Imaging Abnormalities — MRI findings including edema/effusion (ARIA-E) and hemorrhage/hemosiderin deposits (ARIA-H) from anti-amyloid therapy. Usually asymptomatic but can be serious. Higher risk in APOE ε4 homozygotes, on anticoagulants, or with cerebral amyloid angiopathy. Baseline MRI, periodic MRI monitoring, genotype testing, and prescriber vigilance are essential.
How long is Kisunla therapy?
A novel feature: it may allow treatment cessation once amyloid clearance is achieved on follow-up PET imaging (typically 12–24 months for many patients) — a potentially finite course, different from Leqembi (continuous). Discuss with your neurologist for an individualized plan.
Take Control of Your Medication Costs
Disease-modifying Alzheimer’s therapy for early symptomatic patients — accessible therapy matters for cognitive preservation. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.